NCT00589602 · REGISTRY CONDITION SEARCH

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2017-05-30

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing the T cells from the donor cells before transplant may stop this from happening. Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying T-cell depletion in donor stem cell transplant followed by delayed T cell infusions in treating patients with hematologic cancer or other disease.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Treatment-related Mortality (TRM)

→

outcome · POSTED

The Rate of Acute Graft Versus Host Disease (GVHD)

→

outcome · POSTED

Number of Participants With Duration of Absolute Neutropenia

→

outcome · POSTED

Number of Participants Able to Receive T-cell Add Backs

→

outcome · POSTED

Number of Participants With Relapse-free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Diagnosis of any of the following hematologic cancers or other diseases: * Acute myelogenous leukemia * Relapsed or refractory disease with poor-risk cytogenetics * Acute lymphoblastic leukemia * Relapsed or refractory disease with poor-risk cytogenetics * Chronic myelogenous leukemia * Persistent disease after at least 6 months of treatment with imatinib mesylate (Gleevec) * Myelodysplasia, meeting 1 of the following criteria: * French-American-British Classification of refractory anemia with excess blasts (RAEB) or RAEB with transformation * International Prognostic Scoring System score \> 2 * Lymphoid malignancies, including non-Hodgkin lymphoma, Hodgkin disease, chronic lymphocytic leukemia, and prolymphocytic leukemia * Relapsed or refractory disease after at least 1 prior therapy * Myelofibrosis * Transfusion dependent (RBC's, platelets, or both) * Paroxysmal nocturnal hemoglobinuria (transfusion dependent) * Myeloproliferative disorder * Eosinophilic leukemia * Severe aplastic anemia * Corrected reticulocyte count \< 1% * Platelet count \< 30,000/mm³ (untransfused) * Bone marrow biopsy with \< 15% cellularity * Plasma cell leukemia * No essential thrombocytopenia or polycythemia vera * No matched related donor available * Must have an 8/8 or 7/8 serologic HLA matched unrelated donor available PATIENT CHARACTERISTICS: * Cardiac ejection fraction ≥ 45% (if \< 45%, then cardiac consult required) * Not pregnant or nursing * Negative pregnancy test * FEV\_1 and DLCO ≥ 45% predicted * Creatinine \< 2.0 mg/dL * Bilirubin \< 2.0 mg/dL * HIV negative PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior allogeneic bone marrow transplantation * No concurrent administration of steroids with T-cell add-backs INCLUSION CRITERIA: * Patient actual weight must not be greater than 1.5x their ideal body weight * Cardiac ejection fraction \>45%. If less than 45%, a Cardiac consult will be obtained. * A suitably matched unrelated donor that is at least a 7 out of 8 HLA serologic match. * Patient is not pregnant. * FEV 1 and DLCO \> 45% predicted on pulmonary function testing. * Serum creatinine \<2.0 mg/dl, serum bilirubin \<2.0 mg/dl. * Patient and donor are HIV negative. * Diagnosis of one of the following diseases * Acute myelogenous leukemia * Relapsed disease, * Refractory disease, or * With poor-risk cytogenetics * Acute lymphoblastic leukemia * Relapsed disease, * Refractory disease, or * With poor-risk cytogenetics * Chronic myelogenous leukemia * Persistent disease after at least 6 months of treatment with Imatinib Mesylate (Gleevec) * Myelodysplasia * FAB Classification of RAEB or RAEB-T -Or- * IPSS score \>2 * Lymphoid malignancies, including non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia and prolymphocytic leukemia * Relapsed or refractory disease after at least 1 prior therapy * Myelofibrosis * Transfusion dependence (RBC's, platelets, or both) * Paroxysmal Nocturnal Hemoglobinuria (PNH) * Transfusion dependent * Myeloproliferative Disorder * Eosinophilic Leukemia * Severe aplastic anemia (\<1% corrected reticulocyte count, \<30,000 untransfused platelet count, bone marrow biopsy with \<15% cellularity) * Plasma cell leukemia * Patients with ET or PV will not be candidates unless their disease has transformed to end stage myelofibrosis or acute leukemia, for which eligibility criteria for myelofibrosis or acute leukemia would apply. * Patient must signed written informed consent. EXCLUSION CRITERIA: * Inability to give informed consent * Absence of any of the above mentioned medical conditions * Availability of matched-related donor * History of prior allogeneic BMT
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT. Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'
intervention Names
Procedure: peripheral blood lymphocyte therapy
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation (TBI)
label
T-Cell Depletion Transplant
type
EXPERIMENTAL

interventions

arm Group Labels
T-Cell Depletion Transplant
description
T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.
name
peripheral blood lymphocyte therapy
other Names
T-cell depletion
type
PROCEDURE
arm Group Labels
T-Cell Depletion Transplant
description
Allogeneic Hematopoietic Stem Cell Transplantation
name
allogeneic hematopoietic stem cell transplantation
type
PROCEDURE
arm Group Labels
T-Cell Depletion Transplant
description
Peripheral blood stem cell transplantation
name
peripheral blood stem cell transplantation
type
PROCEDURE
arm Group Labels
T-Cell Depletion Transplant
description
Treatment will be delivered using 6MV photons twice daily for 3 days
name
total-body irradiation (TBI)
type
RADIATION

Study design

allocation

intervention Model

SINGLE_GROUP

intervention Model Description

Allogeneic Hematopoietic Stem Cell Transplantation

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 13
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The complication rate in matched unrelated donor (MUD) allogeneic bone marrow transplant (allo BMT) is known to be high. Graft failure and severe graft versus host disease (GvHD) are the most significant contributors to treatment related mortality (TRM). This treatment regimen will be considered unacceptable if the number of patients that experience TRM is 55% or greater, and effective if TRM is 33% or less.
measure
Treatment-related Mortality (TRM)
time Frame
180 days after transplant

secondary Outcomes

measure
The Rate of Acute Graft Versus Host Disease (GVHD)
time Frame
D+100 from transplant
measure
Number of Participants With Duration of Absolute Neutropenia
time Frame
D+100 from transplant
description
Patients receive defined doses of donor T cells by IV infusion on days 45 and 100, in absence of active graft-versus-host disease (GVHD) requiring steroids.
measure
Number of Participants Able to Receive T-cell Add Backs
time Frame
through D+100
description
number of patients that were still alive and relapse free
measure
Number of Participants With Relapse-free Survival
time Frame
after 7 years of follow up

Full study description

brief Summary: RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing the T cells from the donor cells before transplant may stop this from happening. Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying T-cell depletion in donor stem cell transplant followed by delayed T cell infusions in treating patients with hematologic cancer or other disease.
detailed Description: OBJECTIVES: Primary * Determine if T-cell depletion of a peripheral blood progenitor cell (PBPC) graft followed by delayed add-backs of defined doses of donor lymphocytes decreases the rate of graft-versus-host disease and its complications in matched unrelated donor (MUD) allogeneic peripheral blood progenitor cell (PBPC) transplantation in patients with hematologic cancers or other diseases. * Determine whether targeted T-cell dosages in the PBPC graft can be achieved in these patients by positive CD34+ selection using the Baxter Inc. Isolex 300i v. 2.5. * Determine the effects of T-cell depletion on the rate of engraftment in these patients. * Develop a matched unrelated donor (MUD) allogeneic transplantation regimen that will decrease overall treatment-related mortality in these patients. OUTLINE: This is a non-randomized study. * Myeloablative preparative regimen: Patients receive cyclophosphamide IV once daily on days -5 and -4 followed by total body irradiation twice daily on days -3, -2, and -1. Patients also receive tacrolimus on day -1 administered by continuous IV infusion over 24 hours. * Peripheral blood progenitor cell graft transplantation: Patients receive T-cell depleted, peripheral blood progenitor cells (PBPC) by IV infusion on day 0. Beginning 1 day after completion of the PBPC infusion, patients receive filgrastim (G-CSF) subcutaneously once daily until blood counts recover. * Post transplantation T cell add-backs: Patients receive defined doses of donor T cells by IV infusion on days 45 and 100, in the absence of active graft-versus-host disease (GVHD) requiring steroids\*. NOTE: \*A T cell add-back may be given in the presence of GVHD, if the investigator considers the risk from relapse or overwhelming viral infection to outweigh the risk of exacerbating GVHD. Patients will be followed periodically for relapse and survival.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2ebf82d7ec02ecb56576
requested nct id
NCT00589602
primary nct id
NCT00589602
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
334975fbf5afb4019521f86f642e1f9c49096cb6d131b911e3330cf976b5389f
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2ebf82d7ec02ecb56576
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00589602
occurrences
context exact
NCT00589602
end
11
exact text
NCT00589602
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/377/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
02c349220e65f7e62f8184f4a1c53f02a30fdd171ea18b7e54e45581a4ec4a8b
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice